Assessing cognition in patients with early Alzheimer’s disease – an experts views on the new FDA guidance
John Harrison
A recent commentary published in Alzheimer's Research and Therapy highlights the benefits and flaws of the new FDA guidelines for Alzheimer's drug… Read more »
